First-line sugemalimab versus placebo, in combination with chemotherapy, for mNSCLC: 4-year outcomes from GEMSTONE-302

Four-year outcomes from the multicenter phase 3 GEMSTONE-302 trial in China found that sugemalimab plus platinum-based chemotherapy showed a superior long-term overall survival benefit compared with placebo plus platinum-based chemotherapy, as first-line treatment for metastatic NSCLC without known sensitizing EGFR, ALK, ROS1, or RET genomic alterations. The authors conclude that these results underscore the efficacy of sugemalimab plus platinum-based chemotherapy as a standard first-line treatment option for both squamous and non-squamous mNSCLC while maintaining a manageable safety profile.